Treatment of Helicobacter pylori infection 14-day concomitant quadruple therapy versus triple therapy: A parallel double-blind randomized controlled trial

Mohamed Hichem Loghmari; Firas Aissaoui; Arwa Guediche; Wided Bouhlel; Mejda Zakhama; Nabil B Chaabene; Amel Rehaiem; Nouha Ben Abdeljalil; Manel Njima; Abdelfetteh Zakhama; Yosr Kadri; Maha Mastouri; Leila Safer

doi:10.1002/hsr2.1593

Treatment of Helicobacter pylori infection 14-day concomitant quadruple therapy versus triple therapy: A parallel double-blind randomized controlled trial

Health Sci Rep. 2023 Oct 4;6(10):e1593. doi: 10.1002/hsr2.1593. eCollection 2023 Oct.

Affiliations

¹ Department of Hepato-Gastroenterology Fattouma Bourguiba University Hospital Monastir Tunisia.
² Department of Pathological Anatomy Fattouma Bourguiba University Hospital Monastir Tunisia.
³ Microbiology Laboratory Fattouma Bourguiba University Hospital Monastir Tunisia.

Abstract

Background and aims: Successful Helicobacter pylori (Hp) eradication with the traditional 7-day course of proton pump inhibitor triple therapy is declining. Prolonging therapy to 14 days is associated with better eradication rates. Most learned societies recommend concomitant quadruple therapy (QC) as a first-line alternative therapy for this bacterial infection. The aim of this study is to compare the efficacy and safety of triple therapy (TT) and QC for the eradication of Hp infection.

Methods: A parallel double-blind randomized controlled trial was conducted. The diagnosis of Hp infection was made by pathological examination of gastric biopsies. Patients were randomly assigned to two treatment groups: either QC (esomeprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily) or triple therapy (esomeprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses) for 14 days. The efficacy of the treatment is defined by Hp eradication attested by a negative breath test performed 6 weeks after the completion of treatment. Treatment outcomes were compared using the chi-square test, while binary logistic regression identified predictors of treatment failure.

Results: Ninety-two patients were included. Forty-two patients belonged to the QC group and 50 to the TT group. No significant difference was noted between the two groups concerning the rate of Hp eradication either by intention to treat (81% vs. 72% respectively, p = 0.31) or per protocol (81.6% vs. 76.1% respectively, p = 0.54). Likewise, there was no difference between the two groups in terms of tolerance to treatment (59.5% for QC vs. 58% for TT, p = 0.88). No factor has been associated with treatment failure.

Conclusion: There was no significant difference in the rate of HP eradication between the QC and the 14-day triple therapy. Neither regimen should be used topically because of their low eradication rates.

Keywords: Helicobacter pylori; breath test; eradication; quadruple concomitant therapy; triple therapy.